Karaciğer transplantasyon hastalarında klinik eczacılık hizmetlerinin değerlendirilmesi
Küçük Resim Yok
Tarih
2024
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
İnönü Üniversitesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Amaç: Bu araştırmanın amacı Karaciğer Nakli Enstitüsü'nde yatan hastalara klinik eczacılık hizmetlerinin sunulması; ilaç ilişkili sorunların (İLİS) saptanması ve çözüm önerilerinin ilgili hekimle ve/veya diğer sağlık personeli ile sözlü olarak paylaşılması yoluyla klinik eczacının katkısının ortaya konmasıdır. Materyal ve metot: Çalışma 1 Mayıs-30 Ekim 2023 tarihleri arasında İnönü Üniversitesi Turgut Özal Tıp Merkezi Karaciğer Nakli Enstitüsü'nde yürütülmüştür. Bu zaman aralığında Karaciğer Nakli Enstitüsü'nde servis ve yoğun bakımda yatan, karaciğer nakli alıcısı olan ve en az 1 ilaç kullanan hastalarda gözlenen İLİS'ler prospektif olarak değerlendirilmiştir. Bu sorunların sınıflandırılmasında Avrupa Farmasötik Bakım Ağı (PCNE) v.9.1 sınıflandırma sistemi kullanılmıştır. İLİS tespit edilen ve edilmeyen hastalarda klinik ve demografik veriler kıyaslanmıştır. Bulgular: Çalışmaya dahil edilen 373 hastanın 311'inde en az bir İLİS tespit edilmiş ve 373 hastada toplam 620 İLİS kaydedilmiştir. İLİS tespit edilen hastaların kullandığı ilaç sayısının medyan değeri 16 (ÇAA: 12-20), İLİS olmayan hastalarda ise medyan değeri 13.5 (ÇAA: 8-27) olarak bulunmuştur (p<0.05). Çalışmada sorumlu hekim ve hemşireye 620 öneri yapılmış ve bunların 547'sinin (%88,2) kabul edildiği, 73 (%11,8) tanesinin ise kabul edilmediği saptanmıştır. İLİS'lerin nedenlerine göre dağılımı incelendiğinde ''doz seçimi'' (N3) ile ilgili nedenlerin %44,2 ile en sık neden olduğu, bunu %26,1 ile ''ilaç seçimi' (N1) başlığının izlediği görülmüştür. Çalışma kapsamında en az bir komorbidite varlığı, diyabet ve akut böbrek hasarı varlığının İLİS riskini artırdığı bulunmuştur (p<0.05). Sonuç: Multidisipliner sağlık ekibinin bir parçası olarak klinik eczacının, İLİS tespitinde ve yönetiminde rol alarak tedavi başarısına katkı sunabildiği görülmektedir.
Aim: The aim of this study was to provide clinical pharmacy services to patients hospitalized in the Liver Transplant Institute and to reveal the contribution of the clinical pharmacist by verbally sharing possible drug-related problems (DRP) and solution suggestions with the relevant physician and/or other healthcare personnel. Material and method: The study was conducted at Inonu University Turgut Özal Medical Center Liver Transplant Institute between May 1 and October 30, 2023. During this period, DRPs observed in patients who were hospitalized in the ward and intensive care unit of the Liver Transplant Institute, who were liver transplant recipients and who were taking at least 1 drug were prospectively evaluated. The Pharmaceutical Care Network Europe (PCNE) v.9.1 classification system was used to classify these problems. Clinical and demographic data were compared in patients with and without DRP. Findings: At least one DRP was detected in 311 of the 373 patients included in the study and a total of 620 DRP were recorded in 373 patients. The median value of the number of drugs used by patients with DRP was 16 (range: 12-20), while the median value was 13.5 (range: 8-27) in patients without DRP (p<0.05). In the study, 620 suggestions were made to the responsible physician and nurse and 547 (88.2%) of these were accepted and 73 (11.8%) were not accepted. When the distribution of DRPs according to their causes was analyzed, it was found that ''dose selection'' (C3) was the most common cause with 44.2%, followed by ''drug selection'' (C1) with 26.1%. The presence of at least one comorbidity, diabetes and acute kidney injury were found to increase the risk of DRP (p<0.05). Conclusion: As part of a multidisciplinary healthcare team, the clinical pharmacist can contribute to treatment success by taking part in the identification and management of DRP.
Aim: The aim of this study was to provide clinical pharmacy services to patients hospitalized in the Liver Transplant Institute and to reveal the contribution of the clinical pharmacist by verbally sharing possible drug-related problems (DRP) and solution suggestions with the relevant physician and/or other healthcare personnel. Material and method: The study was conducted at Inonu University Turgut Özal Medical Center Liver Transplant Institute between May 1 and October 30, 2023. During this period, DRPs observed in patients who were hospitalized in the ward and intensive care unit of the Liver Transplant Institute, who were liver transplant recipients and who were taking at least 1 drug were prospectively evaluated. The Pharmaceutical Care Network Europe (PCNE) v.9.1 classification system was used to classify these problems. Clinical and demographic data were compared in patients with and without DRP. Findings: At least one DRP was detected in 311 of the 373 patients included in the study and a total of 620 DRP were recorded in 373 patients. The median value of the number of drugs used by patients with DRP was 16 (range: 12-20), while the median value was 13.5 (range: 8-27) in patients without DRP (p<0.05). In the study, 620 suggestions were made to the responsible physician and nurse and 547 (88.2%) of these were accepted and 73 (11.8%) were not accepted. When the distribution of DRPs according to their causes was analyzed, it was found that ''dose selection'' (C3) was the most common cause with 44.2%, followed by ''drug selection'' (C1) with 26.1%. The presence of at least one comorbidity, diabetes and acute kidney injury were found to increase the risk of DRP (p<0.05). Conclusion: As part of a multidisciplinary healthcare team, the clinical pharmacist can contribute to treatment success by taking part in the identification and management of DRP.
Açıklama
Anahtar Kelimeler
Eczacılık ve Farmakoloji, Pharmacy and Pharmacology
